CDKN2A and breast carcinoma: Complete p16 inactivation occurs in only 1.5% of 9p deleted cancers by homozygous deletion and inactivating p16 mutations – that might accompany some of the 9p deletions – occur in only 0.5 to 7% of breast cancers [12, 28–31]).